The Medicines Company Announces Clive Meanwell, MD, PhD, Chief Executive Officer, Is the Recipient of the 2016 Dr. Sol J. Barer Award for Vision, Innovation and Leadership

05 Feb 2016

The Medicines Company (NASDAQ:MDCO) today announced that its founder and Chief Executive Officer, Clive Meanwell, MD, PhD, has been awarded the 2016 Dr. Sol J. Barer Award for Vision, Innovation, and Leadership. Named for Sol J. Barer, PhD, founder and former Chairman and Chief Executive Officer of Celgene Corporation of Summit, New Jersey, the award recognizes outstanding research and business leaders who have made significant contributions to the growth and prosperity of the biosciences industry in New Jersey and throughout the world.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160205005411/en/

<p>
  The award was presented last evening during ceremonies celebrating 
  BioNJ’s 23<sup>rd</sup> Annual Dinner Meeting and Networking Event held 
  at the Hilton East Brunswick. (<a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvimeo.com%2F153283511&amp;esheet=51273786&amp;newsitemid=20160205005411&amp;lan=en-US&amp;anchor=click+here&amp;index=2&amp;md5=acee4ee413187cf39255474fc339165f" rel="nofollow">click 
  here</a> to view Gala video).
</p>
<p>
  “Dr. Sol Barer is an icon of the bioscience industry, and his dedication 
  and commitment to innovation is nothing short of inspirational. I humbly 
  accept this award on behalf of all of my colleagues at The Medicines 
  Company who achieved so much during 2015 – and we thank the BioNJ Board 
  of Trustees for this honor,” said Clive Meanwell, MD, PhD, Chief 
  Executive Officer, The Medicines Company.
</p>
<p>
  “Clive is everything a leader should be: a visionary who’s not afraid to 
  challenge the status quo, an innovator who’s respected by patients and 
  caregivers for his compassion and commitment to better understand their 
  challenges, and a leader who knows how to get the job done and how to 
  inspire a team to travel that road with him,” said Debbie Hart, 
  President and Chief Executive Officer, BioNJ. “Since its inception in 
  1996, Clive has carefully guided The Medicines Company to the innovative 
  institution it is today – known for developing products that industry 
  experts have dubbed ‘game-changers’ in treating cardiovascular disease, 
  infectious disease and sedation. At the same time, Clive has long been 
  committed to understanding how customers value medicines, and ensuring 
  the company delivers both medical and economic improvements that create 
  value and build a sustainable business. Clive is so deserving of this 
  award.”
</p>
<p>
  At the same event, The Medicines Company was one of 16 companies who 
  received a BioNJ Innovator Award for a new drug approval in 2015. The 
  company had four drug approvals in the U.S. in 2015.
</p>
<p>
  <b>About the Dr. Sol J. Barer Award</b>
</p>
<p>
  The Dr. Sol J. Barer Award for Vision, Innovation, and Leadership was 
  established by the BioNJ Board of Trustees in March 2008 as an annual 
  award to recognize the outstanding research and business leaders who 
  have made and continue to make significant contributions to the growth 
  of the biosciences in New Jersey and around the world. The honoree is 
  voted on by the BioNJ Board of Trustees from nominations taken from the 
  Nominating Committee. The award is named for Dr. Sol J. Barer, Ph.D., 
  who founded the biotechnology group at Celanese that was subsequently 
  spun out to form Celgene, currently one of the world’s largest 
  biotechnology companies.
</p>
<p>
  <b>About The&nbsp;Medicines Company</b>
</p>
<p>
  The&nbsp;Medicines Company's&nbsp;purpose is to save lives, alleviate suffering 
  and contribute to the economics of healthcare by focusing on 3000 
  leading acute/intensive care hospitals worldwide. Its vision is to be a 
  leading provider of solutions in three areas: acute cardiovascular care, 
  surgery and perioperative care and serious infectious disease care. The 
  company operates in the&nbsp;Americas,&nbsp;Europe&nbsp;and the&nbsp;Middle East, and&nbsp;Asia 
  Pacific regions with global centers today in&nbsp;Parsippany, NJ, USA 
  and&nbsp;Zurich,&nbsp;Switzerland.
</p>
<p>
</p>


Contacts

The Medicines Company
Media:
Bob Laverty, +1-973-290-6162
Mobile: +1-609-558-5570
Vice President, Communications
Robert.Laverty@themedco.com
or
Investor Relations:
Krishna Gorti, MD, +1-973-290-6122
Vice President, Investor Relations
Krishna.Gorti@themedco.com

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com